FDA investigates Salmonella in moringa leaf powder, expands recall

FDA Investigates Salmonella in Moringa Leaf Powder, Expands Recall

Key Takeaways

• The FDA is conducting an ongoing investigation into a Salmonella outbreak linked to moringa leaf powder.
• Total Nutrition Inc. has expanded a recall of dietary supplements containing moringa leaf powder.
• The FDA advises consumers not to eat or sell recalled dietary supplements containing moringa leaf powder.
• B2B teams in supplement manufacturing, distribution, and retail should cross-reference their inventory against the recall list.

IntelligenceRegulatory Impact▾

FDA decisions frame this story. Regulatory relevance is medium for Salmonella. Track designations, submission types, and label or guidance shifts that could move timelines.

FDA Investigation and Recall Expansion

The FDA is conducting an ongoing investigation into a Salmonella outbreak linked to moringa leaf powder. Total Nutrition Inc. has expanded a recall of dietary supplements containing moringa leaf powder due to the outbreak.

The FDA's public guidance is clear: consumers should not eat or sell recalled dietary supplements containing moringa leaf powder. This advisory applies equally to businesses handling affected products. The investigation remains active, and B2B teams should monitor the FDA's outbreak investigation page for updates on the scope and status of the recall.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low for Salmonella. Expect implications for pricing, access, and launch sequencing.

What B2B Teams Should Know About the Moringa Leaf Powder Recall

A recall tied to a botanical ingredient in dietary supplements creates immediate operational questions for manufacturers, distributors, and retailers. Supplement manufacturers relying on moringa leaf powder as a raw material must assess their current inventory and determine which products may be affected. Distributors and retailers need to reconcile their stock against the recall list and understand the FDA's guidance that recalled products must not be sold.

The expanded recall from Total Nutrition Inc. signals that the scope of affected products may continue to evolve. Teams should establish processes to track updates from the FDA and coordinate with suppliers as the investigation proceeds. Compliance and quality functions should ensure that their recall response workflows are aligned with FDA requirements and that any affected inventory is properly identified and segregated.

IntelligenceStrategic Takeaways▾

The FDA is conducting an ongoing investigation into a Salmonella outbreak linked to moringa leaf powder . Total Nutrition Inc. has expanded a recall of dietary supplements containing moringa leaf powder. The FDA advises consumers not to eat or sell recalled dietary supplements containing moringa leaf powder.

Regulatory Context and Ongoing Investigation

The FDA's official investigation page documents the ongoing Salmonella outbreak linked to moringa leaf powder. The agency has made clear that recalled products must not be eaten or sold. For B2B teams, this means that any inventory flagged in the recall must be removed from distribution channels and that communication with customers and suppliers should reflect the FDA's advisory.

The outbreak investigation itself remains open. As the FDA continues its work, additional product details, affected lot numbers, or brand identifications may emerge. Teams should plan for the possibility that the recall could expand further and that supplier or sourcing information may become available as the investigation progresses.

Frequently Asked Questions

Related coverage

• AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands
• Celcuity Expands VIKTORIA-2 Trial as Shares Trade Below Analyst Targets
• Listeria Outbreaks 2026: FDA and CDC Soft Cheese Recall Analysis for Pharma